INDIANA HEALTH COVERAGE PROGRAMS (IHCP) PHARMACY BENEFIT NARCOLEPSY AGENTS PRIOR AUTHORIZATION (PA) REQUEST FORM



CareSource Pharmacy PA Form P.O. Box 8738 Dayton, OH 45401-8738 Fax: 866-930-0019



Today's Date Non-Urgent Urgent			
Note: This form must be completed by the prescribing provider. ***All sections must be completed or the request will be returned.***			
Member's CareSource ID	Member's Da	ate of Birth	
Member's Name	Prescriber's	Name	
Prescriber's Indiana License Number	Specialty		
Prescriber's National Provider Identifier (NPI)	Office Contact	ct	
Prescriber's Fax	Prescriber's	Phone	
Prescriber's Address	Date(s) of Se	ervice:	
	Start Date:		
Diagnosis Description	Diagnosis Co	ode	
Requested Medication	Quantity	Dosing	
PA Requirements for Nuvigil (armodafinil):			
The member is 18 years of age or older and has one of the following diagnoses: □ Bipolar depression in conjunction with appropriate medical intervention(s) • List any other medical intervention(s) being utilized for bipolar depression (e.g., mood stabilizers):			
□ Narcolepsy with excessive daytime sleepiness			
 Obstructive sleep apnea/hypopnea syndrome with residual excessive daytime sleepiness in conjunction with appropriate medical intervention(s) List any other medical intervention(s) being utilized for obstructive sleep apnea (e.g., PAP, OPT, etc.)? 			
□ Shift work sleep disorder			

PA Requirements for Provigil (modafinil):
 The member is 6 years of age or older and has one of the following diagnoses: Attention deficit hyperactivity disorder (ADHD) Narcolepsy with excessive daytime sleepiness
 The member is 18 years of age or older and has one of the following diagnoses: Depression-related fatigue in conjunction with appropriate medical intervention(s) List any other medical intervention(s) being utilized for depression (e.g., antidepressants):
 Idiopathic hypersomnia Obstructive sleep apnea/hypopnea syndrome with residual excessive daytime sleepiness in conjunction with appropriate medical intervention(s) List any other medical intervention(s) being utilized for obstructive sleep apnea (e.g., PAP, OPT, etc.):
 □ Shift work sleep disorder □ Sleep deprivation □ Steinert myotonic dystrophy syndrome □ Unipolar or bipolar depression in conjunction with appropriate medical intervention(s) • List any other medical intervention(s) being utilized for unipolar/bipolar depression (e.g., antidepressants/mood stabilizers):
PA Requirements for Sunosi (solriamfetrol):
The member is 18 years of age or older and has one of the following diagnoses: □ Narcolepsy with excessive daytime sleepiness □ Obstructive sleep apnea/hypopnea syndrome with residual excessive daytime sleepiness in conjunction with appropriate medical intervention(s) • List any other medical intervention(s) being utilized for obstructive sleep apnea (e.g., PAP, OPT, etc.):
Has the member had a previous trial and failure with any of the following in the past year: Modafinil Dates of use: Armodafinil Dates of use: If no, please provide any other medical justification for use:

Member's Name:

PA Requirements for Wakix (pitolisant):		
Sele	ct ONE of the following: The member is six years of age or older and has a diagnosis of narcolepsy with cataplexy or excessive daytime sleepiness	
	The member is 18 years of age or older and has a diagnosis of obstructive sleep apnea/ hypopnea syndrome with residual excessive daytime sleepiness in conjunction with appropriate medical intervention(s) List any other medical intervention(s) being utilized for obstructive sleep apnea (e.g., PAP, OPT, etc.):	
	 Has the member had a previous trial and failure with any of the following in the past year: Modafinil Dates of use: 	
	Armodafinil Dates of use: If no, please provide any other medical justification for use:	
PA R	quirements for Xyrem (sodium oxybate):	
Initia	Authorization	
	The member is seven years of age or older and has narcolepsy with cataplexy or excessive laytime sleepiness diagnosis? • Please provide requested dose per day: • Please provide member's weight (include date of collection):	
Note	Please provide documentation showing continued benefit from the medication (i.e., reduction in frequency of cataplexy, reduction in symptoms of excessive daytime sleepiness, etc.) without significant adverse events (documentation must include most recent chart notes).	
A Re	quirements for Xywav (calcium/magnesium/potassium/sodium oxybates solution):	
Initia	Authorization Select ONE of the following:	
,	ne member is seven years of age or older and has narcolepsy with cataplexy excessive daytime sleepiness diagnosis □ Yes □ No Please provide requested dose per day: Please provide member's weight (include date of collection):	
2) T	ne member is 18 years of age or older and has idiopathic hypersomnia? ☐ Yes ☐ No Please provide requested dose per day:	
Rea	thorization	
Note	Please provide documentation showing continued benefit from the medication (i.e.,reduction in frequency of cataplexy, reduction in symptoms of excessive daytime sleepiness, etc.) without significant adverse events (documentation must include most recent chart notes).	

CONFIDENTIAL INFORMATION

This facsimile and any attached document are confidential and are intended for the use of individual or entity to which it is addressed. If you have received this in error, please notify us by telephone immediately at 1-844-607-2831.

IN-MED-P-2098100b; Issued Date: 7/15/2025

Member's Name: